Moderna Historical Cash Flow

MRNA
 Stock
  

USD 159.56  4.02  2.58%   

Analysis of Moderna cash flow over time is an excellent tool to project Moderna future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Share Based Compensation of 119.9 M as it is a great indicator of Moderna ability to facilitate future growth, repay debt on time or pay out dividends.Financial Statement Analysis is way more than just reviewing and evaluating Moderna prevailing accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Moderna is a good buy for the upcoming year.
Additionally, see Stocks Correlation.
  
Refresh

Moderna Capital Expenditure

(291.47 Million)

About Moderna Cash Flow Analysis

The Cash Flow Statement is a financial statement that shows how changes in Moderna balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Moderna's non-liquid assets can be easily converted into cash.

Moderna Cash Flow Chart

Moderna Cash Flow Statement became part of mandatory reporting in 1987. It is now one of three main statements in accounting used to measure how well a company manages its liquidity and overall cash position. The rate of cash utilization and preservation is now part of the leading indicators of a healthy entity, and the Moderna Cash Flow Statement shows how well the company generates cash to payout debt obligations or to cover ongoing operating expenses.
Moderna Depreciation Amortization and Accretion is projected to increase significantly based on the last few years of reporting. The past year's Depreciation Amortization and Accretion was at 232 Million. The current year Net Cash Flow or Change in Cash and Cash Equivalents is expected to grow to about 4.6 B, whereas Capital Expenditure is forecasted to decline to (291.5 M).

Issuance Purchase of Equity Shares

A component of Net Cash Flow from Financing representing the net cash inflow (outflow) from common equity changes. Includes additional capital contributions from share issuances and exercise of stock options; and outflow from share repurchases.

Net Cash Flow from Financing

A component of Net Cash Flow or Change in Cash and Cash Equivalents representing the amount of cash inflow (outflow) from financing activities; from continuing and discontinued operations. Principal components of financing cash flow are: issuance (purchase) of equity shares; issuance (repayment) of debt securities; and payment of dividends & other cash distributions.

Net Cash Flow from Investing

A component of Net Cash Flow or Change in Cash and Cash Equivalents representing the amount of cash inflow (outflow) from investing activities; from continuing and discontinued operations. Principal components of investing cash flow are: capital (expenditure) disposal of equipment Capital Expenditure; business (acquisitions) disposition [NCFBus] and investment (acquisition) disposal Net Cash Flow Investment Acquisitions and Disposals.

Net Cash Flow from Operations

A component of Net Cash Flow or Change in Cash and Cash Equivalents representing the amount of cash inflow (outflow) from operating activities; from continuing and discontinued operations.
Most accounts from Moderna cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Moderna current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Additionally, see Stocks Correlation.Moderna Depreciation Amortization and Accretion is projected to increase significantly based on the last few years of reporting. The past year's Depreciation Amortization and Accretion was at 232 Million. The current year Net Cash Flow or Change in Cash and Cash Equivalents is expected to grow to about 4.6 B, whereas Capital Expenditure is forecasted to decline to (291.5 M).

Moderna cash flow statement Correlations

Moderna Account Relationship Matchups

Moderna cash flow statement Accounts

201720182019202020212022 (projected)
Capital Expenditure(58.4 M)(105.77 M)(32 M)(68 M)(284 M)(291.47 M)
Depreciation Amortization and Accretion20.54 M24.86 M31 M93 M232 M250.32 M
Net Cash Flow or Change in Cash and Cash Equivalents86.05 M522.88 M(422 M)2.39 B4.22 B4.56 B
Issuance Purchase of Equity Shares212 K564.45 M51 M2.04 B(733 M)(752.29 M)
Net Cash Flow from Financing168 K1.23 B52 M2.03 B(873 M)(895.97 M)
Net Cash Flow from Investing417.36 M(373.09 M)(15 M)(1.67 B)(8.52 B)(8.75 B)
Net Cash Flow Investment Acquisitions and Disposals475.76 M(267.33 M)17 M(1.6 B)(8.24 B)(8.46 B)
Net Cash Flow from Operations(331.48 M)(330.87 M)(459 M)2.03 B13.62 B14.7 B
Share Based Compensation40.05 M72.56 M81 M93 M142 M119.89 M

Be your own money manager

Our tools can tell you how much better you can do entering a position in Moderna without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Insider Screener Now

   

Insider Screener

Find insiders across different sectors to evaluate their impact on performance
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Moderna using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see Stocks Correlation. Note that the Moderna information on this page should be used as a complementary analysis to other Moderna's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.

Complementary Tools for Moderna Stock analysis

When running Moderna price analysis, check to measure Moderna's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moderna is operating at the current time. Most of Moderna's value examination focuses on studying past and present price action to predict the probability of Moderna's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Moderna's price. Additionally, you may evaluate how the addition of Moderna to your portfolios can decrease your overall portfolio volatility.
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Is Moderna's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moderna. If investors know Moderna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moderna listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
2.02
Market Capitalization
61.9 B
Quarterly Revenue Growth YOY
2.13
Return On Assets
0.5
Return On Equity
1.4
The market value of Moderna is measured differently than its book value, which is the value of Moderna that is recorded on the company's balance sheet. Investors also form their own opinion of Moderna's value that differs from its market value or its book value, called intrinsic value, which is Moderna's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moderna's market value can be influenced by many factors that don't directly affect Moderna's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moderna's value and its price as these two are different measures arrived at by different means. Investors typically determine Moderna value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moderna's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.